Instil Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
TIL$6.35-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $6,638 | $8,805 |
| Restricted cash | 166 | 1,830 |
| Marketable securities | 69,491 | 104,510 |
| Prepaid expenses and other current assets | 3,038 | 9,325 |
| Assets held for sale | 112,096 | — |
| Total current assets | 191,429 | 124,470 |
| Property, plant and equipment, net | 126 | 129,406 |
| Operating lease right-of-use assets | 238 | 934 |
| Accrued rent receivable | 7,664 | 4,267 |
| Other long-term assets | 4,066 | 4,490 |
| Total assets | $203,523 | $263,567 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $779 | $659 |
| Accrued expenses and other current liabilities | 4,064 | 7,237 |
| Total current liabilities | 4,843 | 7,896 |
| Contingent consideration | — | 948 |
| Operating lease liabilities, non-current | — | 1,017 |
| Loan payable | 84,806 | 84,187 |
| Other long-term liabilities | 8 | 83 |
| Total liabilities | 89,657 | 94,131 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value $0.000001 per share; 10,000,000 shares authorized; zero shares issued and outstanding as of December 31, 2025, and 2024 | — | — |
| Common stock, par value $0.000001 per share; 300,000,000 shares authorized; 6,781,976 and 6,525,887 shares issued and outstanding as of December 31, 2025, and 2024 | — | — |
| Additional paid-in capital | 840,937 | 824,780 |
| Accumulated other comprehensive loss | (583) | (228) |
| Accumulated deficit | (726,488) | (655,116) |
| Total stockholders’ equity | 113,866 | 169,436 |
| Total liabilities and stockholders’ equity | $203,523 | $263,567 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.